Sinotau Pharmaceutical Group

Established in 2005 and based in Beijing, China, Sinotau Pharmaceutical Group operates as a biopharmaceutical company that provides targeted therapy and precision diagnostic radiopharmaceuticals. The company has molecular imaging bases in Jiangsu, Guangdong and Sichuan. It cooperates with over 300 hospitals, such as Biogen, Merck and abbvie,  and the academic outreach team has more than 100 members. In 2017, the company established Jiangsu and Guangdong Branch.

In December 2021, it obtained a radiation safety license and established Shanghai R&D Center. In July 2023, it raised over CNY 1. 1 billion in series E funding from Beijing GAGE Capital Management Company Ltd. and CCT Fund Management, etc.

The company's product pipelines are divided into two series, which include the radiopharmaceuticals field and the biopharmaceuticals field. The radiopharmaceuticals field focuses on the development of antibody biologics, and can treat patients with tumors, neurodegenerative diseases and autoimmune diseases. The species of the biopharmaceuticals field involved in 18F, 13C and 14C series nuclides. In addition, the company engages in academic promotion through various ways, including public numbers (Hexing Liaowang), literature publication, journal submission, expert collaboration, academic seminar salon, summit forum and clinical trial data interpretation.